Ignite Creation Date:
2024-10-26 @ 3:39 PM
Last Modification Date:
2024-10-26 @ 3:39 PM
Study NCT ID:
NCT06589154
Status:
RECRUITING
Last Update Posted:
None
First Post:
2024-09-06
Brief Title:
The Application of Multimodal Artificial Intelligence Systems in Prostate Cancer Diagnosis and Prognosis Analysis
Sponsor:
None
Organization:
None
Study Overview
Official Title:
The Application of Multimodal Artificial Intelligence Systems in Prostate Cancer Diagnosis and Prognosis Analysis
Status:
RECRUITING
Status Verified Date:
2024-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The application of multimodal data fusion in prostate cancer will bring new opportunities to improve diagnostic accuracy and treatment outcomes By integrating imaging genomics pathology and clinical data we expect to realize precision medicine for prostate cancer and significantly improve the survival prognosis of patients
Detailed Description:
Prostate cancer stands as one of the most prevalent malignancies among men across the globe Global cancer statistics reveal that the number of new prostate cancer diagnoses rises annually
In recent years the advent of multimodal data fusion technology has paved the way for innovative diagnostic and prognostic approaches in prostate cancer For instance the synergy of MRI imaging with clinical indicators such as PSA levels and Gleason scores not only refines the staging of prostate cancer but also sheds light on a patients likely response to treatment and survival outlook
The exponential growth of artificial intelligence particularly the broad adoption of deep learning and machine learning algorithms has emerged as a formidable asset in the realm of multimodal data analysis By developing an AI-driven multimodal data fusion system vast medical datasets can be efficiently processed laying the groundwork for a more nuanced auxiliary diagnostic and therapeutic decision-making framework
In recent years the advent of multimodal data fusion technology has paved the way for innovative diagnostic and prognostic approaches in prostate cancer For instance the synergy of MRI imaging with clinical indicators such as PSA levels and Gleason scores not only refines the staging of prostate cancer but also sheds light on a patients likely response to treatment and survival outlook
The exponential growth of artificial intelligence particularly the broad adoption of deep learning and machine learning algorithms has emerged as a formidable asset in the realm of multimodal data analysis By developing an AI-driven multimodal data fusion system vast medical datasets can be efficiently processed laying the groundwork for a more nuanced auxiliary diagnostic and therapeutic decision-making framework
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None